New diabetes medications, GLP-1 receptor agonists and SGLT-2 inhibitors, offer life-saving cardiovascular and renal benefits. Despite their potential, cost and administrative barriers hinder broader use, leaving many patients without these transformative treatments.

Researchers have discovered a novel insulin inhibitory receptor, named inceptor, which plays an important role in regulating insulin signaling in pancreatic beta cells. Inhibiting inceptor enhances beta cell function and proliferation, offering a potential new therapy for diabetes. This study suggests that targeting inceptor could protect and regenerate beta cells, providing a promising path toward diabetes remission and a future free from this chronic disease.